Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the association of serum organochlorine pesticides (OCPs) and organophosphorus pesticides (OPs) levels and GSTM1/GSTT1 gene polymorphism with bladder cancer (BC).
|
31009110 |
2019 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study focuses on the impact of GSTM1 null genotype on bladder cancer patients' outcome.
|
31646988 |
2019 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The common deletion of the glutathione S-transferase Mu 1 (GSTM1) gene in humans has been shown to be involved in xenobiotic metabolism and associated with bladder cancer.
|
29695243 |
2018 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis suggested that GSTM1-null genotype is associated with an increased bladder cancer risk in the Chinese individuals.
|
30539835 |
2018 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
With regard to BC, an overall odds ratio (OR) of 2.07 [95% confidence interval (CI): 1.38-3.09] for those with GSTM1 and an OR of 2.07 (95% CI: 1.38-3.09) for those with GSTT1 null genotype were reported when exposed to polycyclic aromatic hydrocarbons (PAHs).
|
28403014 |
2018 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the GSTM1-null, GSTT1-null and dual-null GSTM1-GSTT1 genotypes might be associated with the onset of bladder cancer, but additional genetic-epidemiological studies should be conducted to explore this association further.
|
30419877 |
2018 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data indicate that GSTM1 is a susceptibility factor for environmentally triggered bladder cancer rather than for smoking-mediated bladder cancer.
|
28696897 |
2017 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most relevant polymorphisms for occupational bladder cancer risk were GSTM1 and UGT1A, especially when co-occurring (GSTM1 negative and rs11892031[A/A]: 48% cases vs. 38% controls, OR 1.47, 95% CI 0.99-2.20).
|
28696839 |
2017 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The phase II enzymes N-acetyltransferase 2 (NAT2), glutathione S-transferases M1 (GSTM1), and T1 (GSTT1) and the single nucleotide polymorphism (SNP) rs11892031[A/C] reported to be associated with bladder cancer in genome-wide association studies were genotyped.
|
28696895 |
2017 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Stratified analyses of population-based associations indicated increased bladder cancer risk associated with GSTM1-null and GSTM1/GSTT1 double-null genotypes in hospital-based and population-based studies.
|
27911277 |
2017 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, common polymorphisms in GSTA1, GSTM1 and GSTT1 are associated with susceptibility to BC in individuals from BEN areas of Serbia.
|
27568660 |
2016 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 slow genotype, together with GSTM1 null genotype facilitated the development of bladder cancer in almost all ethnic groups.
|
26854433 |
2016 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Besides, meaningful association between individuals who carried the GSTM1 null genotype and increased BCa risk was detected (OR = 1.39, 95%CI 1.28-1.51).
|
27631264 |
2016 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (P interaction ≤ .001), rs11892031 (UGT1A, P interaction = .01), and rs798766 (TMEM129-TACC3-FGFR3, P interaction = .03).
|
26374428 |
2015 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no association between bladder cancer and GSTM1 polymorphism (ORs = 0.64, 95% CI = 0.32-1.29), but the probability of bladder cancer in patients with GSTT1 null genotype (67.9%), was significantly higher from the probability of bladder cancer with GSTT1 normal genotype (43.0%) statistically (ORs = 2.8, 95% CI = 1.16-6.75).
|
25284638 |
2015 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that seven bladder cancer risk-associated variants (rs9642880, rs2294008, rs798766, rs1495741, GSTM1 null, rs17674580 and rs10936599) may be used, collectively, to effectively measure inherited risk for bladder cancer.
|
24740636 |
2014 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cumulative meta-analyses showed a trend of more obvious association between the GSTM1 null variant and risk of bladder cancer in the Chinese Han population as data accumulated by year.
|
24022663 |
2014 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A significantly higher BC risk was associated with GSTM1 null genotype after adjusting to age, sex and smoking habit (OR 1.85, 95 % CI 1.30-2.62; P = 0.001).
|
24919441 |
2014 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The glutathione S-transferase M1-null genotype also enhanced the risk of bladder cancer among subjects exposed to solvents (OR = 6,5, 95% CI = 2.1-19.7, p = 0.001).
|
24914957 |
2014 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combination of the high-risk genotypes (GSTM1 null + GSTT1 null + GSTP1 313 A/G or G/G) demonstrated further increase in the BC risk (OR = 6.64, 95 %CI = 3.63-12.16).
|
23054023 |
2013 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The main RF were a) age and gender (diagnosed at age 65 and over, with a 4:1 ratio of males to females); b) race, ethnicity and geographic location (predominantly in Caucasians and in Southern European countries); c) genetic (N-acetyltransferase-2 and glutathione s-transferase M1 gene mutations, which significantly increase the risk for BC); d) occupational, which represent 5%-10% of BC RF; and f) occupations with high BC risk, such as aluminium production, the manufacture of dyes, paints and colourings, the rubber industry and the extraction and industrial use of fossil fuels.
|
23664103 |
2013 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GSTM1-null and GSTA1-low activity genotypes are associated with enhanced oxidative damage in bladder cancer.
|
23394311 |
2013 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study was carried out in UBC subjects (n=50) and healthy control subjects (n=50) with an aim to determine the role of GSTM1 and GSTT1 polymorphism and its implication on the OCP detoxification or bioaccumulation which may increase the risk of UBC in humans.
|
24240585 |
2013 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, in association with smoking, both low activity GSTA1 and GSTM1-null genotype increase individual susceptibility to bladder cancer.
|
24075358 |
2013 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The GSTP1 Val/Val genotype was significantly associated with bladder cancer (OR = 4.32, 95% CI: 2.64-6.34), whereas the association observed for GSTM1 null (OR = 1.32, 95% CI: 0.82-2.62; P = 0.67) and GSTT1 null genotype (OR = 1.18, 95% CI: 0.79-1.67; P = 0.74) did not reach statistical significance.
|
22154357 |
2013 |